Clinical Trial Update: Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC) [Phase 2]

View source ↗

Summary

A Phase 2 study comparing bevacizumab plus either mFOLFOX6 or FOLFIRI in previously untreated metastatic colorectal cancer with biomarker stratification; result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Bevacizumab (bevacizumab)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Genentech, Inc. | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-08-11